Roivant Sciences Ltd (ROIV) Directors and Executive Officers

Officers & Directors

Ilan Oren
Director

Mayukh Sukhatme
President and Chief Investment Officer and Director

Melissa Epperly
Director

Keith Manchester
Director

Richard Pulik
Chief Financial Officer (Principal Financial Officer)

Daniel Gold
Director

Meghan FitzGerald
Director

James C. Momtazee
Director

Matthew Gline
Chief Executive Officer and Director (Principal Executive Officer)

Matt Maisak
Name

Rakhi Kumar
Chief Accounting Officer (Principal Accounting Officer) ,

Roivant Sciences Ltd currently has 750 employees.

News about Roivant Sciences Ltd Key Personnel

Roivant's Brepocitinib Shows Impressive Efficacy in NIU Study, Shares Authorized for Repurchase of Sumitomo Pharma Stake

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant (Nasdaq: ROIV) and Priovant Therapeutics have recently shared promising results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU). These results have shown the strongest efficacy data for NIU observed to date, providing hope for patients suffering from this condition.
In addition to the successful NEPTUNE study, Roivant s board of directors has authorized a share repurchase program for up to $1.5 billion of the company s...